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The term dementia derives from the Latin
demens (“de”: private, “mens”: mind, intel-
ligence, judgment—“without a mind”).
The American Psychiatric Association
(APA) describes it as “any mental impair-
ment, or global cognitive decline in a
previously unimpaired person” and is
characterized by a deterioration of cog-
nitive, intellectual, emotional, and behav-
ioral skills, severe enough to interfere
with the daily life of its sufferers (APA,
1994). It may be elicited by pathologies
related to aging, stroke and mechanical
injury, or by recurrent use of alcohol
and substance abuse, including smoking
(DeKosky et al., 2010; Rojas et al., 2010;
Brown and Thore, 2011; Rusanen et al.,
2011).
Dementias are far more prevalent in the
elderly, since only about 5% of all reported
cases involve people under 65 years-
old, the so-called “early onset dementias”
(Fadil et al., 2009). In the United States
of America, the prevalence of dementia
in individuals aging 90 or over exceeds
37% (Plassman et al., 2007). According
to estimates from the Alzheimer’s Disease
International (ADI), about 36 million
people around the world are currently
suffering from some sort of dementia
and this number was predicted to be at
least three times higher in 2050 (ADI,
2010). Approximately two-thirds of all
people with dementia live in less developed
regions, and these disorders are considered
a major burden for health care and social
systems in developing countries (Wimo
et al., 2003).
Alzheimer’s disease (AD) is the major
senile dementia, defined as a degenera-
tive, progressive, and irreversible disor-
der, characterized by a gradual loss of
cognitive function and by behavioral dis-
turbances. It most commonly afflicts indi-
viduals over 65 years old, accounting for
more than half of every worldwide demen-
tia cases (LoGiudice, 2002). AD progres-
sion can be ranked into three stages. At
the early stage, the patient has difficulty
in thinking clearly, presenting a concomi-
tant decrease in performance in complex
tasks. At the moderate stage, aphasia is
evident—inefficiency in naming objects or
to choose the right word to express an idea.
In the severe stage, there are prominent
changes in the sleep-wake cycle, psychotic
symptoms, and in the abilities to walk,
talk, and self-care (Herrera-Rivero et al.,
2010). Individuals become strictly depen-
dent of caregivers and their condition
deteriorates when psychiatric symptoms
or often disruptive behavioral changes
develop, imposing greater burden to the
caregivers. Death usually occurs 3–9 years
after the onset of symptoms (Querfurth
and LaFerla, 2010).
Currently there is no effective treatment
to AD and its cause (or causes) remains
to be defined, although factors such as
family history, diet, lifestyle, genetics, and
head injury have been suggested. Familial
AD involves mutations in the amyloid pre-
cursor protein and presenilins 1 and 2
(Rogaev et al., 1995; El Kadmiri et al.,
2013), which cause overproduction of the
β-amyloid protein. Moreover, increased
levels of cholesterol, hypertension, and
diabetes are also involved in AD devel-
opment (Bassil and Mollaei, 2012; Wirz
et al., 2014). An interdependence between
cholesterol metabolism, Apolipoprotein E
genotype and β-amyloid metabolic path-
way has been reported, with implications
to the pathogenesis of AD (Evans et al.,
2004). Clinical findings suggest a lower
risk of AD in individuals using statins
in order to reduce their cholesterol levels
(Shepardson et al., 2011).
A common condition in AD patients
is weight loss, due to malnourishment
induced by poor diet during the progres-
sion of the disease and the gradual impo-
tence of feeding appropriately. A healthy
nutrition, based on the correct selec-
tion and amount of micronutrients, con-
tributes to delaying the cognitive decline
both during aging and in AD patients
(Lee et al., 2009; Spaccavento et al., 2009;
Hadziabdic et al., 2012). Specific foods
and diets have been reported to lower
the risk of AD (Steele et al., 2007). The
Mediterranean diet is based on a dietary
pattern of high consumption of plant
foods (fruits, vegetables, cereals, and nuts),
olive oil as the main source of fat, a
moderate intake of fish, and a low con-
sumption of red meat. It is thus rich
in omega-3 fatty acids, antioxidants and
vitamins, especially B, C, and E (Willett
et al., 1995). Antioxidant species are par-
ticularly important to help maintain the
proper function of the brain (Gomez-
Pinilla, 2008; Polidori et al., 2009), and
their regular intake reduces oxidative stress
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(Steele et al., 2007; Otaegui-Arrazola et al.,
2014).
Oxidative stress is a major harmful fac-
tor during aging and pathological condi-
tions (Finkel and Holbrook, 2000; Freire,
2012). It is involved in the onset and pro-
gression of several neurodegenerative dis-
orders, such as multiple sclerosis (Clausen
et al., 1988; Gilgun-Sherki et al., 2004),
amyotrophic lateral sclerosis (Baillet et al.,
2010; Dias et al., 2013), Batten’s disease
(Clausen et al., 1988), Parkinson’s dis-
ease (Freire and Santos, 2010; Dias et al.,
2013), and AD (Markesbery, 1997; Pratico,
2008; Zhao and Zhao, 2013). Oxidative
stress results from an imbalance between
the levels of reactive oxygen species (ROS)
and endogenous antioxidant mechanisms
(Nunomura, 2013; Padurariu et al., 2013),
which causes structural and functional
impairment of cells by degrading lipids,
proteins, and nucleic acids (Reynolds et al.,
2007), and ultimately results in cell death.
NADPH oxidase (NOX) is one of the
major enzymes involved in the process
of oxidative stress. Its overexpression is
induced especially by microglial activa-
tion in the brain in both acute (Block
et al., 2007) and chronic conditions (Wu
et al., 2003). NOX seems to play a role
in AD, especially by the action of NOX2,
which is upregulated in the brain of
AD patients (Shimohama et al., 2000;
Zekry et al., 2003). NOX2 expression is
induced by the presence of β-amyloid
plaques that stimulate the activation of
microglial NOX leading to superoxide pro-
duction (Wilkinson et al., 2012), which
in turn leads to mitochondrial disfunc-
tion (Guimaraes et al., 2009), cleavage of
nucleic acids (Nunomura et al., 2012),
and proteolysis (Esler and Wolfe, 2001).
There is a direct relationship between the
impairment of cognitive performance of
AD patients and the increase of NOX activ-
ity (Ansari and Scheff, 2012).
Glutathione peroxidase (GSH-Px) is a
free radical scavenger and a key-enzyme
in the endogenous defensive mechanism
against free radicals (Chen and Berry,
2003). Its main role is to protect cells from
ROS by inactivating hydrogen peroxides
and lipid hydroperoxides originated dur-
ing oxidative metabolism (Arthur, 2000).
Accordingly, the decrease of GSH-Px activ-
ity leads to tissue damage and cell death
due to detrimental action of ROS in
increased levels. GSH-Px mechanism of
action is based on the redox ability of thiol
groups of glutathione and the catalytic
reduction of peroxides, either inorganic
(hydrogen peroxide) or organic (lipid
peroxides). Its functioning is selenium-
dependent (Ceballos-Picot et al., 1996),
and a low dietary intake of this element
alters GSH-Px activity (Arthur, 2000).
Selenium (Se) is micronutrient impor-
tant to the maintenance of human health,
and acts on immune defense, thyroid
gland and cardiovascular functions, and
cancer prevention (Finley, 2003; Thomson
et al., 2009; Joseph and Loscalzo, 2013).
Its deficiency results in cardiomyopathy
associated to Keshan disease in children
(Loscalzo, 2014), a pathology especially
observed in regions where the soil is Se-
deficient. As stated above, Se acts as an
antioxidant component, working in com-
bination with GSH-Px. They protect lipids
by catalyzing the reduction of hydrogen
peroxide and phospholipid hydroperox-
ides generated in vivo by ROS (Gamble
et al., 1997).
Se main natural sources are bread,
cereals, seafood, cruciferous vegetables
(mainly broccoli) (Finley, 2005; Finley
et al., 2005), and especially Brazil nut
(Thomson et al., 2008). In an interesting
study, Thomson et al. (2008) showed that
the insertion of two units of Brazil nuts
daily for 12 weeks in the diet increases
Se levels in the humans’ organism and
enhances GSH-Px activity. In an animal
model of Parkinson’s disease, the systemic
administration of Se improved antiox-
idant activity, protecting dopaminergic
cells from the deleterious effects of 6-
hydroxydopamine (Zafar et al., 2003),
reinforcing the notion of its action in
the redox balance in the brain. Se also
combines with amino acids to form small
peptides called selenoproteins (Papp et al.,
2010), which exert antioxidant activities
as enzymes (Takemoto et al., 2010; Zhang
et al., 2010) and help block ROS involved
in cell collapse, as it is seen in AD (Filipcik
et al., 2006).
The physiological actions of micronu-
trients can be enhanced by their
association with vitamins, which also play
a significant role in reducing oxidative
stress in the brain (Morris et al., 1998;
Heo et al., 2013; Dysken et al., 2014). In
this context, two vitamins are particularly
important: vitamin C (ascorbic acid),
considered the most important soluble
antioxidant, able to neutralize ROS before
the initiation of lipid peroxidation (Heo
et al., 2013); and vitamin E, an important
liposoluble antioxidant that is beneficial
particularly at the membrane level, pro-
tecting polyunsaturated fatty acids from
peroxidation (Tewari et al., 2014). The
ingestion of high-dose vitamins E and C
supplements may lower the risk of AD (Li
et al., 2012; Heo et al., 2013; Dysken et al.,
2014).
The clear-cut effects of dietary intake
on overall health is well-established
(Vermeer et al., 2003), and evidence
suggests that nutritional deficiency
contributes to the development of neu-
ropathological conditions (Gillman et al.,
1995). In a recent meta-analysis, Li et al.
(2012) concluded that clinical studies
about dietary intake of vitamins E, C, and
β-carotene point to a positive role of these
elements in prevention and interventional
treatment of AD. Regarding Se, studies in
humans confirm its participation in the
prevention and treatment of brain dis-
orders, either isolated or in combination
with other elements (Sanmartin et al.,
2011). Smorgon et al. (2004) described
a direct correlation between the reduced
Se plasma concentration and the decline
of cognitive function in AD patients
when compared to healthy individuals.
Such event can be related to the pro-
cess of oxidative stress reported in AD.
Accordingly, in a recent study Olde Rikkert
et al. (2014) found lower levels of Se in the
plasma of non-malnourished patients in
the early stage of AD when compared
to healthy controls, suggesting that dif-
ferences in nutritional status are present
in AD even in the absence of malnutri-
tion (Smorgon et al., 2004; Cardoso et al.,
2010; Vural et al., 2010; Olde Rikkert et al.,
2014).
Nonetheless, despite the correlations
between some nutrients and cognitive
function, more research has yet to be
realized about the likely wide-ranging
impact of nutrition and its benefits
to neurodegenerative diseases. Overall, a
diet including minerals and vitamins,
especially associated to physical activity,
importantly contributes to the attenua-
tion of oxidative stress in the brain (Ma,
2008; Morris, 2009; van Praag, 2009).
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In addition, it is important to remark
that the improvement of general nutri-
tional status should be preferably based
on food sources instead of alternative sup-
plementation practices, since the form-
ers are more accessible, sustainable, and
present lower risk of toxicity than the lat-
ters (Finley, 2005).
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